SynthesisPLoS neglected tropical diseases2020
Prognostic factors for mortality among patients with visceral leishmaniasis in East Africa: Systematic review and meta-analysis.
Synthesis in PLoS neglected tropical diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Prevalence of human visceral leishmaniasis and its risk factors in Eastern Africa: a systematic review and meta-analysis.Frontiers in public health · 2024Pooled it
- Prevalence of hepatitis B and C virus infections among visceral leishmaniasis patients: a systematic review and meta-analysis.Frontiers in microbiology · 2024Pooled it
- Trial
- Systemic inflammatory markers of visceral leishmaniasis treatment response in East Africa.PLoS neglected tropical diseases · 2026Article
- Prognostic models predicting clinical outcomes in patients diagnosed with visceral leishmaniasis: a systematic review.BMJ public health · 2026Article
- Interleukin-8 Predicts Fatal Kala-Azar: A Case-Control Study.Tropical medicine and infectious disease · 2025Article
- Relationship Between Hepcidin, Iron Metabolism, Inflammation and Hypersplenism in Anaemia of Kala-Azar.Parasite immunology · 2025Article
- Hemophagocytic lymphohistiocytosis secondary to visceral leishmaniasis in children: case report and systematic review.Frontiers in pediatrics · 2025Article
- Visceral Leishmaniasis Service Delivery in Somalia: A Comprehensive Literature Review.Research and reports in tropical medicine · 2025Review
- T-cell and Soluble Co-inhibitory Receptor Expression in Patients With Visceral Leishmaniasis Are Markers of Treatment Response and Clinical Outcome.Open forum infectious diseases · 2024Article
- Cytokine profiles, blood parasite load and clinical features of visceral leishmaniasis in West Pokot County, Kenya.Parasitology · 2024Article
- Epidemiological and clinical trends of visceral leishmaniasis in Portugal: retrospective analysis of cases diagnosed in public hospitals between 2010 and 2020.Infectious diseases of poverty · 2024Article
- Factors associated with survival in patients with visceral leishmaniasis treated at a reference hospital in northern Minas Gerais - Brazil.Revista da Sociedade Brasileira de Medicina Tropical · 2024Article
- Burden of neglected tropical diseases and access to medicine and diagnostics in Ethiopia: a scoping review.Systematic reviews · 2023Article
- From Infection to Death: An Overview of the Pathogenesis of Visceral Leishmaniasis.Pathogens (Basel, Switzerland) · 2023Review
- Hematological and Clinical Features Associated with Initial Poor Treatment Outcomes in Visceral Leishmaniasis Patients with and without HIV Coinfection in Gondar, Northwest Ethiopia.Tropical medicine and infectious disease · 2023Article
- Evidence map of diagnosis, treatment, prognosis, prevention, and control in visceral leishmaniasis.Revista panamericana de salud publica = Pan American journal of public health · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVisceral leishmaniasis (VL) is a vector-borne disease that is deadly if left untreated. Understanding which factors have prognostic value may help to focus clinical management and reduce case fatality. However, information about prognostic factors is scattered and conflicting. We conducted a systematic review and meta-analysis to identify prognostic factors for mortality among VL patients in East Africa. METHODOLOGY/PRINCIPAL
findingsThe review protocol was registered in PROSPERO (CRD42016043112). We included studies published in English after 1970 describing VL patients treated in East African health facilities. To be included, studies had to report on associations between clinical or laboratory factors and mortality during admission or during VL treatment, with a minimal study size of ten patients. Conference abstracts and evaluations of genetic or immunological prognostic factors were excluded. We searched for studies in MEDLINE and four other databases in December 2018. To assess the risk of bias in observational studies and clinical trials, we used the Quality in Prognostic Studies (QUIPS) tool. We included 48 studies in the systematic review, describing 150,072 VL patients of whom 7,847 (5.2%) died. Twelve prognostic factors were evaluated in five or more studies and these results were submitted to meta-analysis producing one pooled crude odds ratio (OR) per prognostic factor. The following factors were strongly (OR>3) and significantly (P-value<0.05) associated with mortality: jaundice (OR = 8.27), HIV (OR = 4.60), tuberculosis (OR = 4.06), age >45 years (OR = 3.69), oedema (OR = 3.52), bleeding (OR = 3.37), and haemoglobin ≤6.5 g/dl (OR = 3.26). Factors significantly and moderately (OR between one and three) associated with death were severe malnutrition, long duration of illness, young age (<5 years), and large spleen size. CONCLUSIONS/SIGNIFICANCE: These prognostic factors can be identified by health professionals in resource-constrained settings. They should be considered as "core" prognostic factors in future studies that aim at improving the prognosis of VL patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.